Schedule & Agenda

BIO Digital
Date
  • Show All
Time
  • Show All
  • Show All
  • Show All
Main Therapeutic Focus
  • Show All
Development Phase of Primary Product
  • Show All
Search Sessions
BIO Digital
Jump to Day
19 Results
Not Yet Scheduled
[Not Yet Scheduled]
Iinnovation in the development of vaccines is not just limited to the vaccine itself. Over the last…
Since the first FDA approved bispecific antibody Blincyto hit the market in 2015, a wave of new…
Alzheimer’s disease (AD) and AD-related dementias (ADRD) affect more than 5 million Americans and…
Access to capital is the lifeblood of biotech drug development. There are a number of avenues for…
Countries continue to grapple with pricing combination regimes in oncology, while ensuring timely…
BIO International Convention attendees in San Diego will have the opportunity to hear how a diverse…
How many CRL's are issued because of manufacturing challenges? This aspect of biopharmaceutical R…
The use of real world evidence (RWE) to provide additional data on safety and efficacy of approved…
Applying digital technologies in R&D is estimated to represent a $100 billion opportunity. Much of…
The Federal Lab Consortium (FLC) is a nationwide network representing a non-dilutive, comprehensive…
The promise of gene and cell therapies, advances in genetic screening and related diagnostics, and…
Four gene therapies have been approved by FDA and we’re expecting many more in the coming years…
This panel will bring together a diverse group of experts from across the healthcare industry who…
The Immersive Medicine of the Future (IMoF) will bridge the gap between human clinical needs and…
As the landscape of next generation medicine expands, new opportunities to partner are created…
Over the last decade governments, thought leaders and industry have been discussing the need and…
The American Society of Clinical Oncology’s (ASCO) Annual Meeting brings together more than 30,000…